Celldex Ends Eczema Drug Development After Trial
Celldex Therapeutics has halted development of barzolvolimab for eczema after a mid-stage study did not meet its main goals.
Updated on Nov. 19, 2026 in Biotech

Celldex Therapeutics ended development of barzolvolimab for atopic dermatitis after a mid-stage trial failed to show significant itch reduction. The company's shares fell more than 3% in extended trading.
Why it matters
The failure removes one candidate from the treatment pipeline for eczema, a common skin condition. Celldex will continue late-stage studies of the drug in three hive-related skin conditions.
The mid-stage study enrolled 131 patients with moderate-to-severe atopic dermatitis and found no significant itch reduction after 16 weeks, with no added benefit observed at 32 weeks. The drug was well tolerated, though the company did not address why the mast-cell reduction failed to translate into clinical benefit.
The players
Celldex Therapeutics
Celldex Therapeutics is a publicly traded biotechnology company developing treatments for immune and allergic diseases.
The details
Celldex said barzolvolimab reduced mast cells but that these cells are not the main driver of atopic dermatitis, and the limited improvements fell short of its threshold for further development. The treatment's safety profile was consistent with earlier studies.
Timeline
Week 16: itching measured, with no significant reduction found.
Week 32: no added benefit observed.
November 19, 2026: Celldex announced it would stop eczema drug development.
2027: Celldex plans to seek US approval for chronic spontaneous urticaria.
The Tech Race
The failure of barzolvolimab in eczema tests whether mast-cell depletion, a mechanism Celldex pursued as a therapeutic approach, can deliver benefit beyond the conditions where it is now being studied. Continued late-stage work in chronic spontaneous urticaria will show whether the company's bet on this target holds up in a different disease.
Patients with eczema should not expect barzolvolimab to become available as a treatment, since development in that condition has ended. Those with chronic hives may see the drug advance through later-stage studies, with a US approval filing planned for 2027.
The takeaway
A drug that reduces a target cell type does not automatically treat the disease that cell type is thought to drive. Mid-stage results can redirect a whole program, so readers should weigh early promise against what the trial actually measured.
What happens next
Celldex plans to seek US approval for barzolvolimab in chronic spontaneous urticaria in 2027 and to announce additional indications by year-end.
Further reading
Explore more Biotech coverage for the wider context on drug development pipelines.
Source note: This article includes information reported by WTAQ News Talk | 97.5 FM · 1360 AM | Green Bay, WI.






